Results 81 to 90 of about 24,310,613 (194)

Multitarget Regulatory Mechanisms and Research Advances of Plant‐Derived Bioactive Ingredients in Hypertension Prevention and Management

open access: yesPhytotherapy Research, EarlyView.
Schematic overview of the multi‐target and multi‐pathway mechanisms of PDBI in the prevention and management of hypertension. ABSTRACT Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection.
Qiqi Deng   +6 more
wiley   +1 more source

Domain V Peptides Inhibit β2-Glycoprotein I-Mediated Mesenteric Ischemia/Reperfusion-Induced Tissue Damage and Inflammation

open access: yes, 2010
Reperfusion of ischemic tissue induces significant tissue damage in multiple conditions, including myocardial infarctions, stroke, and transplantation. Although not as common, the mortality rate of mesenteric ischemia/reperfusion (IR) remains >70%.
Sherry D. Fleming   +7 more
core   +1 more source

Conformational Change of β2-glycoprotein I : Evaluation of Difference in Binding Capacity of Autoantibodies to Open and Closed Forms of β2-glycoprotein I

open access: yes, 2013
Antiphospolipidsyndrome (APS) is one of the most common autoimmune diseases characterized bythrombosis, fetal loss and presence of antiphospholipid antibodies.
Wagner, Ylva
core   +3 more sources

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit   +5 more
wiley   +1 more source

Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. [PDF]

open access: yes, 2014
IgG aPL against domain I of β2-glycoprotein I (β2GPI) [anti-DI (aDI)] is associated with the pathogenesis of APS, an autoimmune disease defined by thrombosis and pregnancy morbidity. To date, however, no study has demonstrated direct pathogenicity of IgG
Romay-Penabad, Z   +25 more
core   +1 more source

Evolutionary Mechanisms of Coagulation Factors in Cetaceans During Aquatic Adaptation

open access: yesIntegrative Zoology, EarlyView.
Compared with Bos taurus, T. truncatus showed shorter prothrombin time and thrombin time but prolonged activated partial thromboplastin time, indicating pathway‐specific remodeling of coagulation. Evolutionary analyses identified 18 positively selected genes and accelerated F11 evolution, while functional assays revealed increased coagulation factor ...
Wenjun Lv   +4 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Antiphospholipid Antibodies Bind ATP: A putative Mechanism for the Pathogenesis of Neuronal Dysfunction

open access: yesClinical and Developmental Immunology, 2005
Antiphospholipid antibodies (aPL) generated in experimental animals cross-react with ATP. We therefore examined the possibility that aPL IgG from human subjects bind to ATP by affinity column and an enzyme linked ...
J. Chapman   +4 more
doaj   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy